MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING MODULATOR

• Main Authors: MCCARTNEY JASON, ANTON GULEVICH, SHI YI, BAEK MINSON, PRASUNA PARASELLI, FABRICE JEAN DENIS PIERRE, THOMAS CLEVELAND, ALI KESHAVARZ-SHOKRI, ALEXANDER RUSSELL ABELA, JOHNNY UY, RAYMOND STANLEY GROSS, TERMIN ANDREAS P, FREDRICK F VAN GOOR, TIMOTHY ALCACIO, PRAMOD VIRUPAX JOSHI, PAUL JOHN KRENITSKY, MUNA SHRESTHA, ZHOU JINGLAN, HARIPADA KATSUYA, LORI ANN FERRIS, JEREMY J CLEMENS, ROBERT M HUGHES, SARA SABINA HADIDA RUAH, DAVID ANDREW SIESEL, PAUL TIMOTHY ANGEL, KANG PING, MARK THOMAS MILLER, PETER DIEDERIK JAN GROOTENHUIS, CLARA KUANG-JU HSIA, COREY ANDERSON, KATHY STAVROPOULOS, TIMOTHY JOHN YOUNG
• Format: Patent
• Language: English; Japanese
• Published: 18.10.2023
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

To provide a modulator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing the modulator, methods of treatment of cystic fibrosis, and a process for making the modulator.SOLUTION: The invention provides compounds of Formula (I) in the figure, where: one of Y1 and Y2 is N and the other is CH; X is selected from O, NH, and N(C1-C4 alkyl) groups; and R1 to R6 represent specific substituents.SELECTED DRAWING: Figure 1-1 【課題】嚢胞性線維症膜コンダクタンス制御因子（ＣＦＴＲ）の調節物質、当該調節物質を含有する医薬組成物、嚢胞性線維症の治療方法、及び当該調節物質の作製プロセスを提供すること。【解決手段】式（Ｉ）の化合物：TIFF2023154048000481.tif4298[式中、Ｙ１及びＹ２の一方は、Ｎであり、他方は、ＣＨであり；Ｘは、Ｏ、ＮＨ、及びＮ（Ｃ１－Ｃ４アルキル）基から選択され；Ｒ１～Ｒ６は特定の置換基等を表す]【選択図】図１－１